Re­genxbio looks to part­ner neu­rode­gen­er­a­tive gene ther­a­py work, lays off 15% of staff

Re­genxbio has laid off 15% of its staff as it nar­rows down its pipeline to fo­cus on three gene ther­a­py pro­grams.

The Rockville, MD-based biotech has about 400 em­ploy­ees, ac­cord­ing to re­marks made by pres­i­dent and CEO Ken Mills at an in­vestor con­fer­ence in Sep­tem­ber. That means ap­prox­i­mate­ly 60 staffers were laid off.

Re­genxbio said Wednes­day that the work­ers who are be­ing let go pri­mar­i­ly work in neu­rode­gen­er­a­tive dis­ease de­vel­op­ment, ear­ly re­search and oth­er gen­er­al and ad­min­is­tra­tive ar­eas. The com­pa­ny de­clined to share spe­cif­ic num­bers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.